Vilon
Research OnlyAlso known as: KE, Lys-Glu, Dilysine, KE dipeptide
A synthetic dipeptide (Lys-Glu) developed by Russian scientist Vladimir Khavinson as part of the peptide bioregulation framework. Claimed to support thymus gland function and immune modulation. No Western clinical validation exists; all research originates from Russian institutes.
Research Statistics
Anchor peptide for very-low evidence tier. Russian-only synthetic dipeptide (Lys-Glu) from Khavinson lab; all research from Russian institutes. Minimal published research even by Russian bioregulator standards. No Western replication; immune bioregulation mechanism is purely theoretical.
Research Dossier
Overview
What is Vilon and what does the research say?
Mechanism of Action
The proposed mechanisms of Vilon are based entirely on Russian research. No independent Western validation or controlled human clinical trials exist.
How It Works (Simplified)
Vilon targets immune function through thymus gland modulation:
Proposed to stimulate thymus gland function, promoting thymocyte proliferation and T-cell maturation that typically decline with age.
Short peptides like KE are claimed to penetrate cell nuclei and interact with DNA/chromatin, potentially affecting immune-related gene expression.
Russian studies claim effects on T-cell subpopulations, including helper and cytotoxic T-cells, though mechanisms are not well characterized.
Proposed to modulate cytokine production including IL-2 and interferons, potentially affecting inflammatory and immune responses.
Scientific Pathways
Thymus Stimulation Pathway (Immune Support)
Vilon (KE) → Thymus Gland Interaction → Thymocyte Proliferation
↓
T-Cell Maturation & Differentiation
↓
Enhanced T-Cell Mediated ImmunityEpigenetic Modulation Pathway (Gene Expression)
Vilon → Nuclear Penetration → Chromatin/Histone Interaction → Heterochromatin Decondensation
↓
Immune Gene Expression ChangesNote: These pathways are theoretical constructs based on Russian preclinical research. No independent Western validation confirms these mechanisms in humans.
Important Limitations
- 100% of research from Russian institutes (primarily St. Petersburg Institute of Bioregulation and Gerontology)
- No independent Western replication or validation studies
- No controlled human clinical trials demonstrating immune benefits
- Mechanism of action for a simple dipeptide affecting thymus function is not fully characterized
- Pharmacokinetics, bioavailability, and optimal dosing in humans are unknown
- Comparison to established immunomodulators (like Thymosin alpha-1) shows substantial evidence gap
- Translation from animal studies to human immune benefits is completely unconfirmed
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on preclinical data: Initial interactions with thymic tissue may begin. In vitro studies suggest rapid cellular uptake and chromatin interaction. Any immune parameter changes would not be detectable this early.
Russian protocols suggest continued treatment during this period. Animal studies show progressive changes in thymic architecture over weeks. Gene expression modifications may develop.
Extended treatment in animal models shows more pronounced effects on immune cell populations. Thymocyte counts and T-cell subsets reportedly affected. Human response timeline is unknown.
Long-term effects based on Russian animal studies using cyclical treatment protocols. Optimal human treatment duration and cycling are not established. Sustained immune benefits are unconfirmed.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Vilon product quality
Good Signs (7 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Vilon with other peptides. Based on published research and mechanistic considerations.
Thymalin
CompatibleBoth target thymus function - thymalin is a complex thymic extract while Vilon is a simplified synthetic dipeptide. May have overlapping mechanisms in immune modulation.
Thymogen
CompatibleFellow thymic bioregulator peptides from Russian research. Thymogen (EW) and Vilon (KE) represent different dipeptide approaches to thymus support.
Thymosin-Alpha-1
CompatibleBoth target immune function - Ta1 is a 28-amino acid peptide with FDA orphan drug status, while Vilon is a minimal dipeptide approach. Different evidence quality levels.
Epithalon
CompatibleBoth Khavinson bioregulator peptides with distinct targets - Vilon for thymus/immune, epithalon for pineal/longevity. Often used together in Russian protocols.
Selank
CompatibleBoth Russian peptides with immune-related effects - Selank primarily anxiolytic with secondary immune modulation, Vilon specifically targets thymic function.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Vilon
Related Peptides
Alpha-Defensins
HNP-1, HNP-2, HNP-3 +5 more
A family of small cationic antimicrobial peptides (29-35 amino acids) that are key components of innate immunity in humans. Produced primarily by neutrophils (HNP-1 to 4) and Paneth cells (HD-5, HD-6), they exhibit broad-spectrum antimicrobial activity and immunomodulatory functions. Well-characterized biochemically with extensive research, though therapeutic development faces challenges.
KPV
Lys-Pro-Val, Lysine-Proline-Valine, alpha-MSH(11-13) +1 more
A naturally occurring tripeptide derived from the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). Preclinical studies demonstrate potent anti-inflammatory effects via NF-kB inhibition, but no human clinical trials have been conducted. Research has focused on inflammatory bowel disease and skin inflammation models.
Kristagen
EDG, Glu-Asp-Gly, Immune tripeptide
A synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.
Lactoferricin
LFcinB, Lactoferricin B, LfcinB +1 more
An antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. Shows broad-spectrum antimicrobial activity in laboratory studies. Research focuses on potential applications in infectious disease, food safety, and cancer. Primarily studied preclinically with very limited human clinical data. Not approved as a therapeutic by any regulatory agency.
LL-37
Cathelicidin, hCAP18, Human Cationic Antimicrobial Peptide 18 +3 more
The only human cathelicidin antimicrobial peptide, discovered at Karolinska Institute in Sweden (1995). A 37-amino acid peptide with broad-spectrum antimicrobial activity and immunomodulatory functions. Extensive mechanistic research supports roles in innate immunity, wound healing, and host defense.
Murepavadin
POL7080, RG7929
A first-in-class cyclic antimicrobial peptide targeting the LptD outer membrane protein of Pseudomonas aeruginosa. The first OMPTA (outer membrane protein targeting antibiotic) to reach clinical development. IV formulation discontinued due to nephrotoxicity; inhaled formulation continues Phase 3 development for cystic fibrosis and bronchiectasis patients.